In addition to a significantly increased sensitivity as compared with the initial Phadebas radioallergosorbent test, a major advantage of the Fadal-Nalebuff modified RAST is its correlation with skin testing using skin end point titration. This correlation allows physicians to use both these modalities in the diagnosis and treatment of allergic disorders. However, it has been anecdotally believed that the correlation of radioallergosorbent test classes and skin test end points varied somewhat with different antigens. Fifty-three patients were tested by radioallergosorbent test for 12 inhalant antigens common to the North Texas region. These patients subsequently underwent confirmation of their radioallergosorbent test results by application of intradermal tests at a concentration of one fivefold step weaker than the corresponding radioallergosorbent test level (a "RAST minus one" dilution). The relationship between radioallergosorbent test and skin test results will be critically analyzed.

Objectives/Hypothesis Cis‐platinum is the most frequently used chemotherapeutic agent for the treatment of head and neck squamous cell carcinoma (SCCA). Ototoxicity and nephrotoxicity continue to be the primary dose‐limiting toxicities encountered. Fosfomycin, a broad‐spectrum antibiotic, has been previously shown to be both otoprotective and nephroprotective against cis‐platinum toxicity. Previous in vitro work demonstrated that fosfomycin does not inhibit the tumoricidal actions of cis‐platinum. This study tests whether fosfomycin inhibits cis‐platinum in vivo. Methods An SCCA cell line was grown in vivo in four groups of nude mice, which then received no treatment, standard‐dose cis‐platinum, high‐dose cis‐platinum, or high‐dose cis‐platinum with fosfomycin. Results Fosfomycin did not inhibit the tumoricidal activity of cis‐platinum. Mice treated with fosfomycin also had longer survival, which is probably due to lessening of immediate cis‐platinum systemic toxicity. Conclusion This study shows that fosfomycin in combination with cis‐platinum may be useful in treating advanced, and possibly relatively chemoresistant, SCCA of the head and neck.